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An iTRAQ-based proteomic analysis reveals
dysregulation of neocortical synaptopodin
in Lewy body dementias
Arnab Datta1,2* , Yuek Ling Chai1, Jing Min Tan1, Jasinda H. Lee1, Paul T. Francis3, Christopher P. Chen1,
Siu Kwan Sze4 and Mitchell K. P. Lai1,3*
Abstract
Lewy body dementias are the second most common cause of neurodegenerative dementia in the elderly after
Alzheimer’s disease (AD). The two clinical subgroups of Lewy body dementias, namely, dementia with Lewy bodies
(DLB) and Parkinson’s disease dementia (PDD), are differentiated by the chronology of cognitive symptoms relative
to parkinsonism. At present, there remains a debate on whether DLB and PDD are separate disease entities, or fall
within the same spectrum of Lewy body dementias. In this study, we compared the detergent-soluble proteome
via an 8-plex isobaric tag for relative and absolute quantitation (iTRAQ) analysis of pooled lysates from the prefrontal cortex
(BA9) of DLB (n = 19) and PDD (n = 21) patients matched a priori for amyloid (total Aβ42) burden, semi-quantitative scores
for Lewy bodies and neurofibrillary tangles together with age-matched control (n = 21) subjects. A total of 1914 proteins
were confidently identified by iTRAQ (false discovery rate = 0%). None of the proteins showed a significant yet opposite
regulation in between DLB and PDD when compared to aged controls in the proteomic data set as well as
following immunoblot analysis of the pooled and individual lysates involving all 61 subjects. The postsynaptic
protein, synaptopodin (SYNPO) was significantly down-regulated in both DLB and PDD subgroups, suggesting a
defective synaptic transmission in the demented patients. In conclusion, the largely similar proteome of DLB
and PDD matched for amyloid burden suggests that variations in concomitant AD-related pathology, abnormal
post-translational modifications or protein-protein interactions, defective intracellular trafficking or misfolding of
proteins could play a part in driving the clinically observed differences between these two subgroups of Lewy body
dementias. This further indicates that amyloid-targeting therapeutic strategies may show different efficacies in DLB
versus PDD.
Keywords: Lewy body dementias, Dementia with Lewy bodies, Parkinson’s disease dementia, iTRAQ, Clinical
proteomics, β-amyloid, Aβ42, Synaptopodin
Introduction
Lewy body dementias are increasingly being recognized
as a common cause of old-age dementia, being the third
most prevalent (15–20%) after Alzheimer’s disease (AD)
and vascular dementia (VaD) [1]. They are characterized
by the presence of cortical α-synuclein-positive Lewy
bodies (LBs) and Parkinsonian extrapyramidal motor
symptoms. The two main clinical subtypes of Lewy
body dementias; dementia with Lewy bodies (DLB) and
Parkinson’s disease dementia (PDD) are distinguished
by the temporal relationship between the onset of dementia
and motor symptoms. Therefore, the onset of dementia
preceding, or occurring within one year of motor symp-
toms are diagnosed as DLB, while dementia occurring one
year or more after motor symptoms should be termed as
PDD. This arbitrarily defined ‘one-year rule’ resulted in an
ongoing debate on whether DLB and PDD are “different
points on a common spectrum of Lewy body disease” or
are distinct clinical syndromes [2–4]. DLB and PDD share
clinical features of executive impairment and fluctuating
attention with relatively mild memory impairment [5–7],
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although minor differences may exist in specific domain
subscores [8]. DLB and PDD also manifest similar severity
of motor symptoms [9, 10], comparable Lewy body burden
in most cortical regions [11], and cortical neurochemical
alterations of cholinergic and dopaminergic deficits as well
as losses of nicotinic and glutamatergic GluA receptors
[12–14]. More recent neurochemical studies also reported
deficits in zinc transport and postsynaptic markers in both
DLB and PDD [15]. On the other hand, DLB has variable,
but generally higher, amyloid plaque load compared to
PDD [11, 16, 17] as well as more severe executive impair-
ment and visual hallucinations [3]. In this regard, a system-
atic approach to studying changes in proteomic landscape
may uncover other similarities and differences between
DLB and PDD.
Tissue-based quantitative clinical proteomics has emerged
as an unbiased mechanistic and discovery tool to study vari-
ous neurological disorders. We had pioneered the successful
coupling of isobaric labeling with two dimensional-li-
quid chromatography-tandem mass spectrometry (iTRAQ-
2D-LC-MS/MS) to propose potential therapeutic targets and
biomarkers in ischemic stroke and VaD [18–20]. Although a
similar clinical proteomic approach has been used to study
Parkinson’s disease (PD), few studies have focused on Lewy
body dementias exclusively [21]. Incidentally, two of them
that used an iTRAQ experiment, included either PDD or
DLB as one of the groups and no direct comparison was
made between these two subtypes of Lewy body dementias.
Further, they have used cerebrospinal fluid (CSF) as a
starting sample with an objective to propose candidate
biomarkers for further validation [22, 23]. We could find
only one study that compared brain tissues of a familial
Parkinsonism-dementia complex and DLB on an iTRAQ
platform [24], while studies directly comparing PDD and
DLB have not been reported. Clearly, tissue-based quanti-
tative clinical proteomics remained underutilized despite
its potential to offer a comprehensive insight into the
underlying mechanisms of Lewy body dementia.
Here, using pooled neocortical lysates from a well-
characterized cohort of PDD, DLB and matched control
subjects, we extend the application of the iTRAQ-guided
discovery approach to determine whether these two clin-
ical subtypes of Lewy body dementias have a divergent
molecular signature or share similar aberrant pathways
with varying extent of deregulation. The detergent-soluble
proteomic dataset was filtered with rigorous selection
criteria to shortlist differentially expressed proteins for a
two-step immunoblot experiment on pooled and individ-
ual samples. Proteome-wide comparison of DLB and PDD
preselected for comparable total amyloid β-42 (Aβ42) pro-
tein and amyloid plaque load revealed a grossly similar
pattern of protein expression with a variation in the mag-
nitude of deregulation between these two disorders, indi-
cating an overlapping pathology between DLB and PDD.
Results
The study was divided into three phases; phase –I: Pre-
selection of subjects, phase –II: discovery proteomics
and phase – III: post-proteomic data validation.
Phase –I: Sample matching using total Aβ42 levels
Brain tissue was available from the BA9 area of frontal
cortex of 109 subjects (23 Controls, 52 DLB and 34
PDD). We determined the concentrations of Aβ42 in
BA9 area by ELISA, which showed significantly higher
levels in DLB group compared to the control and PDD
groups (Fig. 1a), in corroboration with previous studies
showing increased Aβ42 load in DLB [25–27]. To study
proteomic changes resulting from processes independent
from those related to AD, we selected a total of 40 Lewy
body dementia (19 DLB and 21 PDD) patients matched
a priori for total Aβ42 concentration, together with 21
control subjects. Other clinical or pathological features
were not considered in the selection of the Lewy body
dementia subjects. Thus, the mean levels of total Aβ42
in DLB and PDD did not differ significantly, although
the DLB group still had significantly higher total Aβ42
compared to the Control group (Fig. 1b).
Demographic and disease variables of participants
Demographic and disease variables of the 61 selected sub-
jects are summarized in Table 1. Age, gender (as % male),
post-mortem interval and tissue pH (as a measure of agonal
status [28]) were matched among control, PDD and DLB
(one-way analyses of variance, (ANOVA) with Bonferroni
post-hoc tests, p > 0.05). PDD patients had longer duration
of Parkinson’s disease symptoms, while DLB showed longer
duration of dementia (Student’s t-tests, p < 0.05). This ob-
servation is consistent with the respective predominant
clinical features of PDD (parkinsonism) and DLB (demen-
tia) over the course of the disease, and indicated clear differ-
entiation of clinical phenotypes between the disease groups.
Lastly, majority of the controls had Braak staging ≤ II and
none had Braak staging > IV, confirming the presence of
only mild age-related pathological changes (Table 1). Figure
2 shows that a priori matching of amyloid plaque load
in DLB and PDD resulted, as expected, in comparable
Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD) scores and neuritic plaques (NP) scores. Neuro-
fibrillary tangles (NFT) scores also did not differ between
DLB and PDD (Fig. 2c). This confirms the matching of
AD-related pathology between DLB and PDD in our study.
However, LB scores remained higher in DLB compared to
PDD (Fig. 2d), in line with previous observations [27].
Phase II: Discovery proteomics
To understand the global proteomic changes that occurred
in the BA9 area of the prefrontal cortex of Lewy body de-
mentias, we pooled equal amount of protein from selected
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subjects group-wise to generate the pooled lysates for PDD
(n = 21), DLB (n = 19), and control (n = 21) groups. Fur-
ther, equal amounts of protein from all 40 dementia (DLB
and PDD) patients were pooled to generate the ‘Dementias’
group. Sample pooling strategy has been used widely to re-
duce the effect of biological variation while dealing with
clinical samples [19, 24, 29]. The labeling scheme for 8-plex
iTRAQ experiment was as follows; control (label: 113, 116),
DLB (label: 114, 117), PDD (label: 115, 118), Dementias
(label: 119) and pooled groups (label: 121), where all
samples across groups were combined.
Quality control of the iTRAQ dataset
To minimize the false positive identification of proteins,
we used a strict cutoff of unused ProtScore ≥ 2 as the
qualification criteria, which corresponds to a peptide
confidence level of > 99%. With this criterion, 1914 pro-
teins were identified from the iTRAQ experiment with a
false discovery rates (FDR) of 0% from the combined
data set containing three technical replicates (Additional
file 1: Table S1). The average number of unique peptides
(having a confidence level of ≥ 95%) detected per protein
was 6.8. More than 29.1% of the proteins (557 proteins)
had ≥ 5 unique peptides, while around 2.1% of proteins
(40 proteins) were identified with ≥ 50 peptide. The
average %coverage for the combined data set was 11.1%,
whereas around 30.4% of the proteins (581 proteins) had
% coverage more than the average level.
Estimation of threshold for confidently defining
perturbed proteins
We determined the cutoff for up- or down-regulation
based on the label-specific experimental variation between
two replicates for the three experimental groups (control:
113, 116; DLB: 114, 117; PDD, 115, 118) [19, 30]. It should
be noted here that variations may arise from handling and
transfer of the samples during gel loading, in-gel digestion,
extraction of digested peptides or during isobaric labeling.
A total of 1988 proteins having ratios were included for this
analysis. Ideally, the ratios between the experimental repli-
cates (116/113, control; 117/114, DLB; 118/115, PDD)
should be equal to one. The frequency distribution of the
fold of deviation from one was measured and plotted for
the three above-mentioned ratios (Additional file 2:
Figure S1). The average experimental variation was
1.11-fold. The experimental variation was ≤1.3 fold for
around 93%, 96% and 94% of the ratios for control, DLB
and PDD groups. Based on this, the regulation cut-off was
set 1.3-fold; ratio > 1.30 and < 0.77 was considered as up-
or down-regulated.
As mentioned above, using duplicate iTRAQ labels for
control, DLB and PDD groups, four ratios were calculated
Fig. 1 Bar charts showing concentrations of total Aβ42 in BA9. a the complete cohort containing 109 subjects and b the 61 subjects (21 Controls,
19 dementia with Lewy Bodies [DLB], 21 Parkinson’s disease dementia [PDD]) selected for the current study. Data were presented as mean ± SEM of
total Aβ42 (ng/mg brain protein). Significant difference (Kruskal Wallis ANOVA followed by post-hoc Dunn’s tests) *p < 0.05 or **p < 0.01
Table 1 Demographic, neurochemical and disease variables of
subjects included in the study
Demographics Control DLB PDD
Number of cases 21 19 21
Age at death (mean yrs. ± SD) 81.7 ± 6.5 80.7 ± 6.2 78.8 ± 6.1
Sex (Male,%) 13 (61.9) 10 (52.6) 11 (52.3)
Post-mortem interval
(mean hrs ± SD)
35.2 ± 22.7 31.8 ± 18.6 33.7 ± 16.1
Tissue pH 6.5 ± 0.3 6.4 ± 0.5 6.5 ± 0.3
Braak Staging (n) 0-II 14 2 13
III-IV 1 13 6
V-VI 0 4 2
NA 6 0 0
CERAD Score (n) None 10 3 5
Sparse 3 8 6
Moderate 0 4 4
Frequent 1 4 5
NA 7 0 1
Lewy Body Score (n) None 19 0 7
Sparse 0 4 9
Moderate 0 5 5
Severe 0 9 0
NA 2 1 0
Abbreviations: DLB, dementia with Lewy body; PDD, Parkinson’s disease
dementia; n, number; NA, not available
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each for DLB (114/113, 117/113, 114/116, 117/116) and
PDD (115/113, 118/113, 115/116, 118/116) group with re-
spect to control, while Dementias group was represented
by two ratios (119/113, 119/116). Overall, the dataset con-
tained ten different ratios when all combinations of repli-
cates were considered. Next, the dataset was filtered based
on the following criteria. (a) The ratios representing DLB,
PDD and Dementias were sorted using a p-value cut-off
of 0.05 (p < 0.05) and a regulation threshold of 1.3-fold to
obtain the list of significantly perturbed proteins. Thirty-
eight proteins with a significant p-value for at least one of
these 10 calculated ratios and a magnitude beyond 1.3-
fold were short-listed. (b) Finally, geometric mean was
calculated from the ratios corresponding to DLB, PDD
and Dementias and filtered with the cut-off of 1.3-fold to
shortlist seven proteins (Table 2).
Considering a situation where the use of too stringent
parameters during dataset filtration may result in the ex-
clusion of an elusive marker protein between DLB and
PDD, we manually curated the iTRAQ dataset to select
additional candidate proteins from the extended list. For
example, vimentin (VIM) was included as it showed an
opposite trend of regulation between DLB (upward trend)
and PDD (downward trend) without crossing the stipulated
threshold of regulation (i.e. 1.3-fold). Neural cell adhesion
molecule 1 (NCAM1) and superoxide dismutase 1 (SOD1)
were included as a negative control as they were signifi-
cantly elevated in BA21 area of subjects with VaD in one of
our recently concluded study [19]. Conversely, SOD1 dis-
played a uniform reduction in the infarcted tissue of stroke
patients when sampled from three different locations of the
brain [18]. Overall, the final list contained twenty-two pro-
teins (Table 2).
Phase III: Post-proteomic immunoblotting
iTRAQ data validation
We selected seven proteins (VIM, synaptopodin (SYNPO),
glutathione S-transferase P (GSTP1), NCAM1, collagen
alpha-3(VI) chain (COL6A3), filamin A, alpha (FLNA) and
myelin proteolipid protein (PLP1)) from Table 2 for valid-
ation on the pooled lysates that were used for the iTRAQ
experiment. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were used as the loading control. As shown in
Fig. 3a-b, the abundance of SYNPO was lower whereas
GSTP1 and PLP1 level were higher in Lewy body demen-
tias and its clinical subtypes. VIM was down-regulated in
PDD. The level of NCAM did not show any variation
among different groups. No clear band could be detected
for COL6A3 and FLNA during the immunoblotting experi-
ment. FLNA and COL6A3 are high molecular weight pro-
teins and were identified with very low sequence coverage
(FLNA, 3.2% and COL6A3, 1.4%; Table 2) in the iTRAQ
experiment indicating the presence of miniscule levels of
these proteins in the original samples. This could have at-
tributed to the poor signals during the immunoblot experi-
ment. Overall, we observed a consistent trend of regulation
Fig. 2 Bar charts showing the neuropathological scores (a CERAD, b neuritic plaque [NP], c neurofibrillary tangle [NFT] and d Lewy Body [LB]) in
the subjects (21 Controls, 19 DLB, 21 PDD), selected for iTRAQ experiment. Data were presented as mean ± SEM. Significant difference (Kruskal
Wallis ANOVA followed by post-hoc Dunn’s tests) *p < 0.05 or **p < 0.01
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for at least four proteins (i.e. GSTP1, PLP1, VIM and
SYNPO) in between the iTRAQ and immunoblot
experiment of pooled lysates.
Immunoblotting of selected protein candidates on
individual subjects
Next, we used the samples of all sixty-one subjects to
probe the levels of the validated candidates by immuno-
blotting. Notably, p-value from the iTRAQ and immu-
noblot experiment of the pooled samples provided an
estimate of the technical variation while p-value for this
experiment will provide an estimate of the biological
variation. This is crucial for the general applicability of
the findings. The abundance of SYNPO was significantly
lower in both PDD (p = 0.030) and DLB (p = 0.024) groups
when compared with the control subjects (Fig. 3c-d).
Further, the level of SYNPO did not differ significantly in
between DLB and PDD group. On the other hand, VIM,
PLP1 and GSTP1 failed to display significant alteration
(p > 0.05) between control and either subtypes of Lewy
body dementias. This indicates that wide biological
variation within a group probably due to wider intra-group
distribution of Braak stages can obscure the trends obtained
from the immunoblot experiment of pooled lysates. Despite
the negative trends for these three proteins, the data has
important ramifications. First, these candidate proteins can
be preferentially selected for a hypothesis-driven study in a
different cohort of Lewy body dementia subjects. They may
have higher chance to show significant difference in de-
mented subjects compared to a randomly selected protein.
Second, if a similar discovery driven study is planned with a
similar experimental design and analysis criteria, these pro-
teins could be the candidate of choice for a meta-analysis.
Correlation analyses
Correlation analyses were performed between the levels
of selected candidate proteins in individual subjects and
various neuropathological variables such as Braak Stage,
CERAD, NP, NFT and LB scores, as well as Aβ42 con-
centrations. SYNPO levels was negatively correlated with
CERAD (ρ = −0.34), NP (ρ = −0.43), LB (ρ = −0.33) and
Aβ42 (ρ = −0.38). Even within the demented subjects,
the correlation remained significant between SYNPO
and NP (ρ = −0.38). In contrast, no significant
correlation was observed between the other candidate
proteins and neuropathological variables, except weak
Fig. 3 Two-step immunoblot analysis of selected proteins. a Representative immunoblots from the pooled lysates showing the protein levels of
Control, DLB, PDD and the combined ‘Dementias’ group, with GAPDH used as the loading control. b Bar chart of immunoreactivities (mean ± SEM in
arbitrary units) for comparing protein expression levels (with mean control values set at 1.0). Dotted lines were drawn at ± 1.3-fold to indicate the
threshold of deregulation as determined from the iTRAQ experiment. The data shows upward trends for GSTP1, PLP1 and downward trends for SYNPO
and VIM while NCAM did not exhibit any change between different groups. c Representative immunoblots of selected proteins using
individual subjects. Control (C), PDD (P) and DLB (D) subjects selected randomly from each group for different proteins. GAPDH was used as
the loading control. d Bar chart of normalized immuno-reactivities (mean ± SEM in arbitrary units) of the proteins of interest was calculated
from all subjects (21 Controls, 19 DLB, 21 PDD) selected for the iTRAQ experiment. Significant difference (one-way ANOVA followed by post-
hoc Bonferroni tests) *p < 0.05
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correlations were observed with CERAD (VIM,
ρ = −0.27), Aβ42 (VIM, ρ = −0.26) and Braak stages
(GSTP1, ρ = 0.27) among all subjects, but not when lim-
iting to the demented subjects only. Detailed results of
the correlation analyses are listed in Additional file 2:
Table S2.
Discussion
Previous reports are conflicting on whether to classify
PDD and DLB as two clinical subtypes of Lewy body
dementias or consider them as a part of a continuum of
a heterogeneous, single disorder. Since the clinically
adopted ‘one-year rule’ assumes that PDD and DLB have
overlapping disease processes which are distinguished
partly by quantitative differences in the amyloid plaque
load [11, 16, 17], we believed that a proteome-wide com-
parison of DLB and PDD subjects that were matched by
the tissue concentration of total Aβ42 and amyloid plaque
load could settle this ongoing debate. The frontal cortex is
critically involved in the cognitive processes and have been
found by us and others to be subject to Lewy body path-
ology and neurochemical deficits [27, 31]. Santpere et al.
found network level disruption of gene regulation includ-
ing those involved in energy metabolism, protein folding
and synaptic function [32]. Therefore, we selected a de-
fined region of the prefrontal cortex (i.e. BA9) as a prom-
ising target for our proteomic analyses.
Lack of substantial differences in proteomic signature
between DLB and PDD
Our proteomic study consisted of an imprint from the BA9
area of neocortex containing 1914 proteins (FDR = 0%)
from a surfactant-soluble fraction. In contrast, a previous
iTRAQ-based study that used a surfactant-insoluble fraction
isolated from the temporal lobe identified 106 proteins
[24]. In our study, microtubule-associated protein 2,
COL6A3, and FLNA were down-regulated only in PDD
without showing any change in DLB samples. ‘Demen-
tias’ group gave consistent pattern of response in most
occasions thus cross-verifying the technical reliability of
the iTRAQ experiment. In general, although PDD appeared
to elicit wider perturbation of brain proteome compared to
DLB based on the iTRAQ dataset and immunoblotting of
pooled samples (Fig. 3a-b), the direction of deregulation
was largely similar between these two subtypes of Lewy
body dementias. Intriguingly, not a single protein from
the shortlist (Table 2) showed opposite trend of regulation
between PDD and DLB that is beyond the specified
threshold of 1.3-fold. Unsurprisingly, the two-step immu-
noblot experiments involving pooled and individual sub-
jects, failed to identify any protein that varies significantly
between DLB and PDD (Fig. 3). This indicates that the
clinically defined differences may not be driven by alter-
ations in crude abundances of total protein levels in
between DLB and PDD. This provides additional justifica-
tion as to why studies using traditional approaches (e.g.
ELISA) and targeting either CSF or blood failed to validate
a single circulatory protein biomarker that can distinguish
between DLB or PDD [33].
Differences between DLB and PDD is likely driven by
different burdens of concomitant Alzheimer’s pathology
The next question we faced was why no wide differences
were observed in total protein-levels despite scanning
almost 10% of human proteome. Whilst much of the
available literature have shown an overlapping neuro-
psychology and neuropathology between DLB and PDD
without clear-cut neurochemical differences between
the two subtypes of Lewy body dementias, we were never-
theless able to gather a few studies that have reported
differences between DLB and PDD using a multitude of ap-
proaches ranging from neuropathological, neurochemical
to neuroimaging avenues [34, 35]. For example, using a
neuroimaging approach that involves the use of [11C]
Pittsburgh Compound B (PIB)-PET, an earlier and more
extensive cortical Aβ deposition was shown in DLB com-
pared to PDD [26]. Intriguingly, the reported differences in
all the above-mentioned studies have been attributed to an
underlying Aβ pathology. It is well known that apart from
α-synuclein positive LBs and Lewy neurites, Alzheimer’s
pathology co-exists in both DLB and PDD in the form of
amyloid plaques as well as neuritic elements [35]. Aβ42, the
42-amino acid peptide derived from the amyloid precursor
protein, is the main constituent of amyloid plaques.
Accordingly, we measured the levels of total Aβ42 for
the complete cohort of Lewy body dementia patients
to estimate the relative involvement of Aβ pathology
between DLB and PDD groups. We detected signifi-
cantly higher levels of Aβ42 in DLB when compared to
PDD or control group (Fig. 1a) which corroborates
earlier findings showing higher Aβ burden in various
brain regions of DLB patients [25–27]. As the total
Aβ42 fractions include fibrillar Aβ42 which constitutes
amyloid plaques [36], measurements of total Aβ42 is
likely to provide a good estimate of amyloid plaque
burden. Given that the matching of DLB and PDD subjects
by total Aβ42 burden resulted in no candidate protein
which could differentiate DLB from PDD in the proteomic
dataset, it is therefore likely that the bulk of proteomic
differences between DLB and PDD are driven by a con-
comitant Alzheimer’s pathology. This finding is consistent
with recent studies where major overlap of CSF Aβ42 pro-
file has been found between DLB and AD patients [37] and
an aberrant CSF Aβ42 level predicted cognitive decline in
DLB and PD patients [38, 39]. Alternatively, it may suggest
the involvement of abnormal post-translational modifica-
tions or protein-protein interactions, defective intracellular
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trafficking or structural anomalies such as aberrant protein
folding in the pathogenesis of Lewy body dementias.
Unchanged expression of α-synuclein (SNCA)
SNCA, being the major constituent of LBs and Lewy
neurites, is the focus of several genetic and biomarker
studies in Lewy body dementias that failed to provide
any consistent trend [35]. In another iTRAQ-based study,
SNCA was identified as a surfactant insoluble protein in
the frontal cortex where only one peptide was detected for
SNCA, isoform 2–4 [24]. We identified at least six peptides
for SNCA from the surfactant soluble fraction with a se-
quence coverage of 65.7%. We did not observe any alter-
ation in the levels of SNCA in between the subtypes of
dementia or control subjects in the iTRAQ dataset. This
agrees with the above study where SNCA showed compar-
able levels between Parkinsonism-dementia complex and
DLB when triton X-100 insoluble fractions from neocortex
was tested by ELISA [24]. However, the higher LB loads in
DLB compared to PDD observed in our cohort (Fig. 2d)
suggests that other species of SNCA, e.g., those phosphory-
lated at Serine129, may be more directly implicated in LB
pathogenesis [40] and should be further investigated.
Importantly, none of the candidate proteins correlated
with LB scores within the Lewy body dementias group
(Additional file 2: Table S2), suggesting that differences
in LB loads between DLB and PDD do not underlie
their proteomic differences.
Decrease in SYNPO level is indicative of a synaptic
decline in Lewy body dementias
Dysfunctional Synaptic transmission is a known con-
tributing factor for various types of dementia such as
AD and VaD. Hence, we searched the dataset for various
synaptic markers that were confidently identified in this
cohort of subjects. Notable candidates were Synaptophysin,
Synaptosomal-associated protein 25, Rab3A and SYNPO
(Table 2). However, except SYNPO, none of them showed
deregulation. SYNPO is enriched in post-synaptic dendritic
spines of mature neurons and used as a marker of dendritic
spines. It is a cytoskeletal protein that directly binds with F-
actin like FLNA and may regulate spine morphology, motil-
ity and activity-dependent spine plasticity [41, 42]. To our
knowledge, a couple of studies have examined the role of
SYNPO in various forms of dementia. SYNPO was signifi-
cantly decreased in frontal and parietal cortices of both
early and definitive AD patients compared to age-matched
control subjects [43]. Another study noted reduced density
of SYNPO-labeled spine puncta only in AD cases with
dementia, while SYNPO-labeled dendritic spines were
maintained in pathologically confirmed AD with normal
cognition [44]. Hence, the reduction of SYNPO probably
indicates a declining synaptic function in the prefrontal cor-
tex which may contribute to dementia. Perhaps, as SYNPO
is detectable in plasma exosome and it shows lower level in
patients with frontotemporal dementia and AD [45], a simi-
lar trend could be obtained in subjects of Lewy body de-
mentias thus making it a potential biomarker candidate.
Overall, considering that a synaptic protein presents a clear
difference in its abundance, it will be worthwhile to target a
synaptosomal preparation from autopsied tissues for similar
studies in the future.
It is important to note the limitations of the study. First,
a postmortem study captures a terminal snapshot of the
proteome. It is possible that the proteomic landscape is
distinct between DLB and PDD during the early stages of
the disorders that converge into a set of common molecu-
lar pathways at an advanced stage making both subtypes
virtually indistinguishable in terms of proteomic signature.
However, it is difficult to collect matched brain samples at
various time points during the temporal evolution of the
disorder. Prospective studies through neuroimaging or
systems biological approaches involving CSF specimens
sampled at multiple time-points are important follow-up
studies to the current observations. Second, it should be
kept in mind that despite having targeted the whole prote-
ome, we have analyzed the SDS soluble fraction of the
brain proteome only. Plaques and aggregates such as LBs,
amyloid deposits are poorly soluble in strong ionic deter-
gents and can get lost during protein extraction even
when 2% SDS is used. This could offset the significantly
high difference of LB score between control and diseased
groups resulting in false negatives. To check this, we com-
pared the protein recovery (%weight of starting tissue)
among the three groups (control, DLB and PDD). We as-
sume that if the aggregates (amyloid plaques or LBs) are
lost during protein extraction, the protein yield should be
considerably low for DLB and PDD groups compared to
control as there is higher proportion of aggregates in the
diseased subjects. Further, proteins integral to LBs and
amyloid deposits should show an artefactual down-
regulation in DLB or PDD group due to incomplete
sampling. However, no significant decrease was observed
in between the mean protein recovery of any two groups
(Additional file 2: Figure S2). In addition, SNCA and
Amyloid beta A4 protein, which are the main component
of LBs and amyloid aggregates respectively, had been
confidently detected by the iTRAQ experiment without
showing any deregulation. Further SNCA was one of the
top 15 proteins in the dataset when sorted in terms of se-
quence coverage. Overall, non-uniform extraction with 2%
SDS is unlikely to change the major conclusions of this
study. Third, as Braak stages are linked to plaques
and tangle burden, incomplete extraction of proteins
with increasing Braak stages could lead to artifacts
during group-wise comparison of proteomic land-
scape. To check the possible extent of confounding
related to non-uniform distribution of Braak stages
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among different groups, we analyzed the relationship
of protein yield with Braak stages (n = 55) using
Spearman rank (ρ) correlation. This was followed by
one-way ANOVA where mean protein recovery of all
subjects, stratified into three categories of Braak stages
(i.e. 0-II, III-IV, V-VI) were compared. None of them
revealed any significant difference (Additional file 2:
Figure S3) indicating that our extraction protocol
worked uniformly irrespective of the Braak stages of
the subjects. Finally, iTRAQ experiments are well-
known to distort the protein ratios towards unity [46].
That may also contribute to false negatives. Keeping that
in mind, we have used the lowest possible cut-off (i.e. 1.3-
fold) in this study and manually incorporated additional
candidates during short-listing and immunoblot valid-
ation. However, the methodology and MS instrument
used for this study have been successfully utilized in
the past on clinical brain samples to detect low levels
of fold changes [18, 19]. Hence, ‘ratio distortion’ is un-
likely to affect the major findings of this study.
In conclusion, we report one of the largest detergent-
soluble proteomic dataset pertaining to Lewy body de-
mentias using an iTRAQ-2D-LC-MS/MS based clinical
proteomic approach. In this system-wide neuroproteomic
study comparing a well characterized cohort of PDD and
DLB patients pre-selected for comparable total Aβ42 and
amyloid plaque burden, our results indicated a remarkable
lack of differences in total protein levels in BA9 area of pre-
frontal cortex between DLB and PDD. This suggests that
PDD and DLB are likely part of the same spectrum of Lewy
body dementias rather than distinct entities, and the
neurochemical changes noted by us and others [12–15]
may be associated with differential burden of concomitant
AD-related pathology or may be linked to changes in post-
translational modifications or protein-protein interactions,
defects in intracellular trafficking or structural anomalies
such as aberrant protein folding. We also report SYNPO as
a potential candidate biomarker for Lewy Body Dementias.
Our study has implications in the therapeutic approaches
for Lewy body dementias, as amyloid-targeting therapeutic
strategies may be predicted to show different efficacies in
DLB versus PDD.
Methods
Reagents
Unless indicated, all reagents and assay kits were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
Patients and clinical assessments
Postmortem tissues from the prefrontal cortex (Brodmann
area BA9) were obtained from PDD and DLB patients,
along with aged non-demented controls from Stavanger
University Hospital, Newcastle University and the London
Neurodegenerative Diseases Brain Bank, the UK centers
being part of the Brains for Dementia Research network
(http://www.brainsfordementiaresearch.org.uk/). Informed
consent was obtained from subjects or their next-of-kin
prior to the removal of brains, and the study has Institu-
tional Review Board (IRB) approvals from the UK (National
Research Ethics Service 08/H10104) and Singapore
(National University of Singapore IRB 12-062E). Neuro-
pathologic assessments were performed for all subjects,
and included Braak staging of neurofibrillary changes,
CERAD scoring criteria, Newcastle/McKeith Criteria
for Lewy body disease, and National Institute on
Aging—Alzheimer’s Association guidelines. [2, 47–49]
In addition, semi-quantitative scores of NP, NFT and
LB using a four point scale (0, none; 1, sparse; 2, mod-
erate; 3, severe) were assessed as previously described
[27]. Controls were neurologically normal and did not
have any history of dementia or psychiatric disease. For
the patients, final differential diagnoses between PDD
and DLB were based on clinicopathological consensus
diagnosis considering the ‘one-year rule’ [2].
Aβ42 Elisa
To measure total Aβ42 levels which has been shown to
contain the highly aggregated fibrils of Aβ42 found in
neuritic plaques [36], chunks of pre-frontal cortex (BA9)
were homogenized in 5 M guanidine/50 mM Tris-HCl
buffer as previously described [50]. The Aβ42 was
measured using a sandwich ELISA (Invitrogen, Carlsbad,
CA, USA, expressed in ng/mg protein) following the
manufacturer’s protocol.
Sample preparation for proteomics and immunoblotting
Frozen tissue samples from BA9 area were processed as
described earlier with minor modifications [18]. Briefly,
tissue samples were homogenized in lysis buffer [2%
sodium dodecyl sulfate (SDS); 20 mM di-thiothreitol
(DTT), 100 mM Tris, pH 7.9, with protease inhibitor
cocktail (cOmplete™, Roche, Mannheim, Germany) and
2 mg/ml Pepstatin A and PhosSTOP (Roche)] using a
Bullet Blender (Next Advance, New York, NY, USA;
speed 8) for 10 min. The crude extracts were then
centrifuged at 20600 g for 15 min. The supernatant was
mixed with 4 volumes of ice cold 100% acetone by vor-
texing and kept at −20 °C overnight to precipitate the
proteins. The lysates were centrifuged at 15000 g for
10 min to collect the protein pellet. The pellets were
washed with 90% acetone to remove remaining
contaminants and collected by centrifugation at
15000 g for 10 min. The acetone-precipitated proteins
were re-dissolved in lyses buffer (6% SDS, 20 mM DTT,
100 mM Tris, pH 7.9) and stored in aliquots at −80 °C
for long-term use. The samples were processed at 4 °C.
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The protein concentration was determined by 2D Quant
kit (Amersham Biosciences, Piscataway, NJ, USA).
Discovery proteomics
The in-gel digestion, peptide labeling, chromatographic
separation and mass spectrometric analysis were performed
following previously established methods [30, 51] with
minor modifications.
In-gel tryptic digestion and isobaric labeling
The samples (250 μg of protein/group) were subjected
to a denaturing PAGE using a 4% - 6% - 25% gel follow-
ing a similar procedure as described previously [30].
Briefly, proteins were migrated through the 4% into the
6% layer, but were retarded by the 25% layer, thus
concentrating them in a narrow strip at the end of the
stacking gel. The diced gel bands were then reduced
[5 mM tris-(2-carboxyethyl) phosphine, 60 °C, 1 h] and
alkylated (10 mM methyl methanethiosulfonate in iso-
propanol, room temperature, 45 min in the dark) before
being digested with 12.5 ng/μL of sequencing-grade
modified trypsin (Promega, Madison, WI, USA) in
50 mM triethylammonium bicarbonate buffer (TEAB),
2% acetonitrile (ACN) for overnight at 37 °C. The pep-
tides were extracted with 50% ACN, 5% acetic acid and
vacuum-centrifuged to dryness. The dried peptides
were reconstituted into 0.5 M TEAB and labeled with
respective isobaric tags of 8-plex iTRAQ Reagent Multi-
Plex kit (Applied Biosystems, Foster City, CA, USA). The
labeling scheme was as follows; control (label: 113, 116),
DLB (label: 114, 117), PDD (label: 115, 118), Dementias,
i.e. combined samples of all DLB and PDD subjects (label:
119) and pooled groups (label: 121) where all samples
across groups were combined. The labeled samples were
then combined and dried using vacuum-centrifugation.
Electrostatic repulsion and hydrophilic interaction
chromatography (ERLIC)
The mixture of iTRAQ-labeled peptides was fraction-
ated using a PolyWAX LP anion-exchange column
(4.6 × 200 mm, 5 μm, 100 Å) (PolyLC, Columbia,
MD, USA) on a Prominence UFLC system (Shimadzu,
Kyoto, Japan) and monitored at 214 nm. Fifty five
fractions were collected during a 65 min gradient of
100% buffer A (0.1% formic acid (FA), and 10 mM
ammonium formate in 85% ACN) for 5 min, 0–25%
of buffer B (0.1% FA in 30% ACN) for 35 min, 25–
100% of buffer B for 10 min, 100% of buffer B for
10 min, and 100% of buffer A for last 5 min at a flow rate
of 1 ml/min [52]. Eluted fractions were pooled into 20 fac-
tions depending on the peak intensities. They were dried
in a vacuum centrifuge and redissolved in 0.1% FA in 3%
ACN for LC-MS/MS analysis.
Reverse phase LC-MS/MS analysis using QSTAR
Each fraction of redissolved iTRAQ-labeled peptides was
sequentially injected in triplicate and separated in a
home-packed nanobore C18 column (75 μm ID × 15 cm,
2.4 μm particles, Reprosil-Pur C18-AQ, Dr. Maisch GmbH,
Ammerbuch, Germany) with a picofrit nanospray tip (New
Objectives, Woburn, MA, USA) on a Tempo nano-MDLC
system coupled with a QSTAR Elite Hybrid MS (Applied
Biosystems/MDS-SCIEX). Each fraction was independently
analyzed by the LC-MS/MS over a gradient of 90 min with
the constant flow rate of 300 nl/min [29, 30]. Data acquisi-
tion in QSTAR Elite was set to positive ion mode using
Analyst QS 2.0 software (Applied Biosystems, Foster City,
CA, USA). The precursors with a mass range of 300–
1600 m/z and calculated charge from +2 to +5 were
selected for fragmentation. For each MS spectrum, 5 most
abundant peptides at most above a 10-count threshold
were selected for MS/MS, and the selected precursor was
dynamically excluded for 15 s with a mass tolerance of 50
mDa. Smart information-dependent acquisition was acti-
vated with automatic collision energy and automatic MS/
MS accumulation. The fragment intensity multiplier was
set to 20 and maximum accumulation time was 2 s.
Mass spectrometric raw data analysis
Spectra acquired from each of the technical and experi-
mental replicates were submitted alone and together to
ProteinPilot Software (v 3.0, Revision Number: 114,732,
Applied Biosystems) for peak list generation, protein identi-
fication and quantification against the concatenated target-
decoy Uniport Human database (v 120,312). User defined
parameters in ProteinPilot software were configured as de-
scribed previously [51] with minor modifications as follows:
(ii) Specify Processing, Quantitate and Bias Correction.
Default precursor and MS/MS tolerance for QSTAR ESI-
MS instrument were adopted automatically by the software.
The FDR of both peptide and protein identification were
set to be less than 1% (FDR = 2.0*decoy_hits/total_hits).
Immunoblotting
Immunoblotting was performed after 10% or 12% SDS-
PAGE by probing with primary antibodies at the indicated
dilutions: anti-GAPDH (1: 1000, mouse monoclonal;
Milipore, Billerica, MA, USA), anti-COL6A3 (1:200, mouse
monoclonal; Santa Cruz Biotech, Santa Cruz, CA, USA),
anti-GSTP1 (1:1000, rabbit polyclonal; Abcam, Cambridge,
UK), anti-FLNA (1:1000; rabbit polyclonal; Cell Signaling
Technology, Danvers, MA, USA), anti-NCAM (1:10,000,
rabbit polyclonal; Santa Cruz Biotech), anti-PLP1 (1:1000,
rabbit polyclonal; Abcam), anti-SYNPO (1:500, rabbit
polyclonal; Abcam), anti-VIM (1:1000, rabbit poly-
clonal; Genscript, Piscataway, NJ, USA). Twenty to fifty
micrograms of proteins were used depending on the
sensitivity of the specific antibody. Immunoreactivity
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was detected by using an HRP chemiluminescent substrate
reagent kit (Invitrogen, Carlsbad, CA). A pooled sample was
used to normalize the inter-gel variation between repeated
runs for the same protein. Immunoreactivities of antibodies
were visualized with Luminata™ Forte or Crescendo Western
HRP substrate (Merck Millipore, Germany) and quantified
with the Alliance 4.7 image analyser (UVItec, UK).
Statistical analyses
Statistical analyses were performed using SPSS software
version 21 (IBM, Armonk, NY, USA) and GraphPad Prism
(San Diego, CA, USA). Data were first tested for normality
using Komogorov-Smirnov test when deciding the use of
parametric vs. non-parametric tests. Normally distributed
data were compared using one-way ANOVA followed by
post-hoc Bonferroni tests, while ordinal or non-normally
distributed data (i.e., Aβ42 level, CERAD score) were
compared using Kruskal-Wallis ANOVA followed by post-
hoc Dunn’s tests. Similarly, independent-samples t-tests or
Mann-Whitney U tests were used to compare means for
two groups of cases, while correlations between variables
were analyzed with either Pearson’s product moment cor-
relation or with Spearman’s rank correlations. Statistical
significance is accepted at p < 0.05.
Additional files
Additional file 1: Table S1. Complete information of the full list of the
qualified proteins (Unused prot score > 2) obtained from the bias
corrected iTRAQ data set. (XLSX 555 kb)
Additional file 2: Figure S1. Frequency distribution of fold variation
between the experimental replicates. Figure S2. Interleaved scatter plot
showing the protein yield (% tissue weight) across three groups (control,
DLB and PDD). Figure S3. Interleaved scatter plot showing the changes
in protein yield (% tissue weight) with increasing Braak stages. Table S2.
Correlation between selected candidates’ protein levels and neuropathological
variables of the subjects included in the study. (DOCX 268 kb)
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